RLAY - סך החוב של החברה Relay Therapeutics, Inc.

The price trend illustrated in this chart allows for an assessment of the debt load of Relay Therapeutics (RLAY), which utilizes AI-driven protein dynamics modeling to accelerate the synthesis of oncology drugs. The company's future market position is based on the high efficacy of innovative medicines, the cost of which reaches 0.03. Currently, the business relies on investment capital, as the clinical trial stage has not yet generated a stable cash flow.

This metric aggregates all of the company's creditor obligations to assess its financial stability. By analyzing the volume of debt capital, an investor determines the company's degree of dependence on borrowed funds and the cost of servicing liabilities. The metric measures default risk by comparing debt growth rates with liquidity. This is critical for Relay Therapeutics (RLAY), as computational drug discovery requires capital-intensive investments. The stability of this indicator confirms the autonomy of the scientific-structural cycle from macroeconomic fluctuations.